---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-23-000036"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T07:47:26.812852+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Travere reports Q2 loss, FILSPARI launch progress, and $445M bile acid portfolio sale

## Summary
- Net loss $85.6M ($1.13/share) vs $67M loss in prior year; revenue $59.7M from product sales $57M and licensing.
- FILSPARI launch: 417 new patient start forms in Q2; net sales $3.5M in Q2, $6.5M since Feb approval.
- Positive pegtibatinase Cohort 6 results: 67.1% mean tHcy reduction; Phase 3 study expected by year-end.
- Agreement to sell bile acid portfolio (Cholbam, Chenodal) to Mirum for up to $445M ($210M upfront); close Q3 2023.
- Cash $491.3M; topline confirmatory PROTECT data for IgAN sNDA expected late Q3/early Q4.

## SEC filing metadata
- accession: 0001438533-23-000036
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853323000036/0001438533-23-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853323000036/tvtx-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-23-000036
- JSON: https://secwatch.observer/filing/0001438533-23-000036.json
- Plain text: https://secwatch.observer/filing/0001438533-23-000036.txt

## Key facts
- Earnings Releases
  Travere Therapeutics, Inc. reported the second quarter of 2023 results: revenue $59.7 million, net income $1.13 per basic share, EPS $1.13 per basic share.
  - Period: the second quarter of 2023
  - Revenue: $59.7 million
  - Net income: $1.13 per basic share
  - EPS: $1.13 per basic share
  - Result: reported results
  source text: treatment standards from pipeline and strengthens financial foundation; transaction expected to close in third quarter of 2023 • Total revenue for the second quarter of 2023 was $59.7 million, consisting of $57.0 million in net product sales and $2.7 million in licensing and collaboration revenue • Cash, cash equivalents, and marketable securities, as of June 30,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000143853323000036/0001438533-23-000036-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.